CNST Constellation Pharmaceuticals Inc.

36.61
+0.19  (+1%)
Previous Close 36.42
Open 36.63
Price To Book 25.42
Market Cap 945,368,901
Shares 25,822,696
Volume 180,111
Short Ratio
Av. Daily Volume 733,552
Stock charts supplied by TradingView

NewsSee all news

  1. Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  2. Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  3. Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  4. Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  5. Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

    Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%) evaluable

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data at ASH December 9, 2019 noted (spleen volume response) SVR35 80%; (Total Symptom Score >50% improvement) TSS50 71%. Update due mid-2020.
CPI-0610 and ruxolitinib - Manifest
Myelofibrosis
Phase 2 trial initiated.
CPI-1205 ORIOn-E
Solid tumors
Phase 2 data due mid-2020.
CPI-1205 - ProSTAR
Castration-resistant prostate cancer
Phase 1/2 update due 2H 2020.
CPI-0209
Solid tumors

Latest News

  1. Constellation Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  2. Constellation Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  3. Constellation Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  4. Constellation Pharmaceuticals Announces Proposed Public Offering of Common Stock

    CAMBRIDGE, Mass., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., (NASDAQ:CNST) a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  5. Constellation Pharmaceuticals Provides Updated Preliminary Data from MANIFEST Clinical Trial with CPI-0610 in Oral and Poster Presentations at ASH

    Preliminary data showed continuing signs of activity across a broad range of parameters, suggesting possible disease-modifying effects of CPI-0610In the first-line treatment arm, 12 out of 15 (80%) evaluable

  6. Constellation Pharmaceuticals to Host Analyst/Investor Meeting at ASH to Discuss Updated Preliminary Data from the MANIFEST Clinical Trial with CPI-0610

    CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  7. Constellation Pharmaceuticals to Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  8. Constellation Pharmaceuticals Announces MANIFEST Data Updates Will Be Provided in Oral and Poster Sessions on December 9 at ASH

    Company will hold investor event on December 9 at 12:30 PM CAMBRIDGE, Mass., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its

  9. Constellation Pharmaceuticals Announces $65 Million Private Placement with New and Existing Investors

    CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  10. Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel

  11. Constellation Pharmaceuticals Advances CPI-0209 into Clinical Trials, Expanding its EZH2 Franchise

    CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (NASDAQ:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel